Miglustat for treatment of Niemann-Pick C disease: a randomised

Pharmaceutical Benefits Scheme (PBS) Miglustat, capsule, 100 mg, Zavesca® - November 2011

Niemann–Pick disease, type C - Wikipedia

Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka

Cost-effectiveness of miglustat versus symptomatic therapy of Niemann–Pick disease type C

Niemann–Pick Disease Type C: Induced Pluripotent Stem Cell–Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy - Daozhan Yu, Manju Swaroop, Mengqiao Wang, Ulrich Baxa, Rongze Yang, Yiping Yan, Turhan

Niemann- Pick Disease Type C (NPC) Market Report 2023-2033 - Wissen Research

IJMS, Free Full-Text

Frontiers Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases

Recommendations for the diagnosis and management of Niemann–Pick disease type C: An update - ScienceDirect

Miglustat - Wikipedia

Psychiatric and Cognitive Symptoms Associated with Niemann-Pick Type C Disease: Neurobiology and Management

Cost-effectiveness of miglustat versus symptomatic therapy of Niemann–Pick disease type C

Miglustat - LiverTox - NCBI Bookshelf

IJMS, Free Full-Text